BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 35202550)

  • 1. Menin-MLL protein-protein interaction inhibitors: a patent review (2014-2021).
    Bai H; Zhang SQ; Lei H; Wang F; Ma M; Xin M
    Expert Opin Ther Pat; 2022 May; 32(5):507-522. PubMed ID: 35202550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Menin-MLL1 Interaction Small Molecule Inhibitors: A Potential Therapeutic Strategy for Leukemia and Cancers.
    Shi Q; Xu M; Kang Z; Zhang M; Luo Y
    Molecules; 2023 Mar; 28(7):. PubMed ID: 37049787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
    Dzama MM; Steiner M; Rausch J; Sasca D; Schönfeld J; Kunz K; Taubert MC; McGeehan GM; Chen CW; Mupo A; Hähnel P; Theobald M; Kindler T; Koche RP; Vassiliou GS; Armstrong SA; Kühn MWM
    Blood; 2020 Nov; 136(21):2442-2456. PubMed ID: 32589720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
    Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
    Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct pathways affected by menin versus MLL1/MLL2 in MLL-rearranged acute myeloid leukemia.
    Chen Y; Jones KL; Anastassiadis K; Kranz A; Stewart AF; Grembecka J; Meyerson M; Ernst P
    Exp Hematol; 2019 Jan; 69():37-42. PubMed ID: 30315824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Progress of Small Molecule Menin-MLL Interaction Inhibitors as Therapeutic Agents for Acute Leukemia.
    Lei H; Zhang SQ; Fan S; Bai HR; Zhao HY; Mao S; Xin M
    J Med Chem; 2021 Nov; 64(21):15519-15533. PubMed ID: 34726905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia.
    Grembecka J; He S; Shi A; Purohit T; Muntean AG; Sorenson RJ; Showalter HD; Murai MJ; Belcher AM; Hartley T; Hess JL; Cierpicki T
    Nat Chem Biol; 2012 Jan; 8(3):277-84. PubMed ID: 22286128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia.
    Shi A; Murai MJ; He S; Lund G; Hartley T; Purohit T; Reddy G; Chruszcz M; Grembecka J; Cierpicki T
    Blood; 2012 Nov; 120(23):4461-9. PubMed ID: 22936661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
    Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
    J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic implications of menin inhibition in acute leukemias.
    Issa GC; Ravandi F; DiNardo CD; Jabbour E; Kantarjian HM; Andreeff M
    Leukemia; 2021 Sep; 35(9):2482-2495. PubMed ID: 34131281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemias.
    Grembecka J; Belcher AM; Hartley T; Cierpicki T
    J Biol Chem; 2010 Dec; 285(52):40690-8. PubMed ID: 20961854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the undruggable: menin inhibitors ante portas.
    Dempke WCM; Desole M; Chiusolo P; Sica S; Schmidt-Hieber M
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):9451-9459. PubMed ID: 37103568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The MLL-Menin Interaction is a Therapeutic Vulnerability in
    Rasouli M; Blair H; Troester S; Szoltysek K; Cameron R; Ashtiani M; Krippner-Heidenreich A; Grebien F; McGeehan G; Zwaan CM; Heidenreich O
    Hemasphere; 2023 Aug; 7(8):e935. PubMed ID: 37520776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Box of Chemistry to Inhibit the MEN1 Tumor Suppressor Gene Promoting Leukemia.
    Ozyerli-Goknar E; Nizamuddin S; Timmers HTM
    ChemMedChem; 2021 May; 16(9):1391-1402. PubMed ID: 33534953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.
    Borkin D; He S; Miao H; Kempinska K; Pollock J; Chase J; Purohit T; Malik B; Zhao T; Wang J; Wen B; Zong H; Jones M; Danet-Desnoyers G; Guzman ML; Talpaz M; Bixby DL; Sun D; Hess JL; Muntean AG; Maillard I; Cierpicki T; Grembecka J
    Cancer Cell; 2015 Apr; 27(4):589-602. PubMed ID: 25817203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein.
    Murai MJ; Chruszcz M; Reddy G; Grembecka J; Cierpicki T
    J Biol Chem; 2011 Sep; 286(36):31742-8. PubMed ID: 21757704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX/MEIS1 expression.
    Juul-Dam KL; Shukla NN; Cooper TM; Cuglievan B; Heidenreich O; Kolb EA; Rasouli M; Hasle H; Zwaan CM
    Eur J Med Genet; 2023 Dec; 66(12):104869. PubMed ID: 38174649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia.
    Krivtsov AV; Evans K; Gadrey JY; Eschle BK; Hatton C; Uckelmann HJ; Ross KN; Perner F; Olsen SN; Pritchard T; McDermott L; Jones CD; Jing D; Braytee A; Chacon D; Earley E; McKeever BM; Claremon D; Gifford AJ; Lee HJ; Teicher BA; Pimanda JE; Beck D; Perry JA; Smith MA; McGeehan GM; Lock RB; Armstrong SA
    Cancer Cell; 2019 Dec; 36(6):660-673.e11. PubMed ID: 31821784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein Interaction.
    Aguilar A; Zheng K; Xu T; Xu S; Huang L; Fernandez-Salas E; Liu L; Bernard D; Harvey KP; Foster C; McEachern D; Stuckey J; Chinnaswamy K; Delproposto J; Kampf JW; Wang S
    J Med Chem; 2019 Jul; 62(13):6015-6034. PubMed ID: 31244110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-affinity small-molecule inhibitors of the menin-mixed lineage leukemia (MLL) interaction closely mimic a natural protein-protein interaction.
    He S; Senter TJ; Pollock J; Han C; Upadhyay SK; Purohit T; Gogliotti RD; Lindsley CW; Cierpicki T; Stauffer SR; Grembecka J
    J Med Chem; 2014 Feb; 57(4):1543-56. PubMed ID: 24472025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.